ABCELLERA BIOLOGICS - Asset Resilience Ratio

Latest as of June 2026: 32.12%

ABCELLERA BIOLOGICS (8QQ) has an Asset Resilience Ratio of 32.12% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 8QQ working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€420.04 Million

≈ $491.07 Million USD Cash + Short-term Investments

Total Assets

€1.31 Billion

≈ $1.53 Billion USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how ABCELLERA BIOLOGICS's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 8QQ asset base.

Liquid Assets Composition Over Time

This chart breaks down ABCELLERA BIOLOGICS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 8QQ long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€420.04 Million	32.12%
Total Liquid Assets	€420.04 Million	32.12%

Asset Resilience Insights

Very High Liquidity: ABCELLERA BIOLOGICS maintains exceptional liquid asset reserves at 32.12% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

ABCELLERA BIOLOGICS Industry Peers by Asset Resilience Ratio

Compare ABCELLERA BIOLOGICS's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	2.50%
Dianthus Therapeutics Inc. NASDAQ:DNTH	Biotechnology	63.98%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	62.24%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%
Wecome Pharmaceutical Co Ltd SHE:300878	Biotechnology	0.67%
Tectonic Therapeutic, Inc. NASDAQ:TECX	Biotechnology	86.66%
Relmada Therapeutics Inc NASDAQ:RLMD	Biotechnology	95.25%
MediWound Ltd F:M8W	Biotechnology	56.04%

Annual Asset Resilience Ratio for ABCELLERA BIOLOGICS (2021–2025)

The table below shows the annual Asset Resilience Ratio data for ABCELLERA BIOLOGICS.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	29.87%	€405.31 Million ≈ $473.85 Million	€1.36 Billion ≈ $1.59 Billion	-4.62pp
2024-12-31	34.49%	€469.29 Million ≈ $548.65 Million	€1.36 Billion ≈ $1.59 Billion	-7.66pp
2023-12-31	42.15%	€627.26 Million ≈ $733.34 Million	€1.49 Billion ≈ $1.74 Billion	+9.71pp
2022-12-31	32.45%	€499.95 Million ≈ $584.49 Million	€1.54 Billion ≈ $1.80 Billion	+13.73pp
2021-12-31	18.72%	€246.84 Million ≈ $288.58 Million	€1.32 Billion ≈ $1.54 Billion	--

pp = percentage points

About ABCELLERA BIOLOGICS

F:8QQ Germany Biotechnology

Market Cap

$4.17 Billion

€3.56 Billion EUR

Market Cap Rank

#4791 Global

#803 in Germany

Share Price

€11.00

Change (1 day)

+4.76%

52-Week Range

€2.49 - €11.00

All Time High

€44.98